We have located links that may give you full text access.
High frequency hearing loss following treatment for nasopharyngeal carcinoma.
OBJECTIVE: To evaluate the prevalence, severity and differences of high frequency hearing loss in nasopharyngeal carcinoma patients after curative treatment by radiotherapy alone and chemoradiation.
MATERIAL AND METHOD: Pure tone audiometry was done in nasopharyngeal carcinoma patients who came back to follow-up after curative treatment during the year 2003 and 2004. The patients were divided into three groups, the first group received radiation treatment only, the second group received radiation and cisplatin chemotherapy, and the third group received radiation and carboplatin chemotherapy
RESULTS: Of 192 patients with a mean age 49.9 years, mean radiation dose 6,951.5 cGy, mean follow-up period 3 years and 9 months, 93.8% showed bilateral high frequency hearing loss. There were statistically significant differences in the high frequency hearing threshold between the second group versus the first and the third group.
CONCLUSION: Clinicians should inform patients of the risk of hearing loss, particularly the treatment with cisplatin. Hearing test should be a routine test after treatment completion.
MATERIAL AND METHOD: Pure tone audiometry was done in nasopharyngeal carcinoma patients who came back to follow-up after curative treatment during the year 2003 and 2004. The patients were divided into three groups, the first group received radiation treatment only, the second group received radiation and cisplatin chemotherapy, and the third group received radiation and carboplatin chemotherapy
RESULTS: Of 192 patients with a mean age 49.9 years, mean radiation dose 6,951.5 cGy, mean follow-up period 3 years and 9 months, 93.8% showed bilateral high frequency hearing loss. There were statistically significant differences in the high frequency hearing threshold between the second group versus the first and the third group.
CONCLUSION: Clinicians should inform patients of the risk of hearing loss, particularly the treatment with cisplatin. Hearing test should be a routine test after treatment completion.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app